Safety and immunogenicity of an autoclaved <i>Leishmania major</i> vaccine
نویسندگان
چکیده
منابع مشابه
Safety and immunogenicity of an autoclaved Leishmania major vaccine.
OBJECTIVE To test the safety and immunogenicity of two doses of autoclaved L. major (ALM) vaccine mixed with BCG. SETTING Kala-azar endemic area of eastern Sudan. DESIGN This was a randomised, double blind and BCG controlled phase I/II study. SUBJECTS Eighty healthy volunteers (forty children and forty adults) with no past history of kala-azar, no reactivity to leishmanin antigen and with...
متن کاملSafety and Immunogenicity of Hepatitis B Vaccine: a Study on Iranian Navy Personnel
Objective: Preventing communicable diseases in the armed forces (AF) of a country is considered as a national interest and has a great importance. There are limited data on the efficacy of vaccination of the navy personnel. This study was designed to evaluate both the safety and the immunogenicity of a recombinant hepatitis B (HB) vaccine made by Pasteur Institute of Iran (IPI-rHB), in this tar...
متن کاملSafety and immunogenicity of hepatitis B vaccine ButaNG in adults
Recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan was administered in two groups of adult volunteers (I, II) following two different schedules of immunization. In the first trial (10 &mgr;g doses and 0, 1, 3 months vaccination schedule) 106 individuals completed the full immunization program. The results of seroconversion by age group varied from 70 to 100% and th...
متن کاملSafety and immunogenicity of a Plasmodium vivax sporozoite vaccine.
A recombinant DNA Plasmodium vivax sporozoite vaccine containing the repeating region of the Salvador I strain circumsporozoite (CS) protein was produced in Escherichia coli. This vaccine was tested in 13 naive volunteers at doses of 10-1,000 micrograms. No serious adverse reactions were noted. None of 4 volunteers receiving the 10 micrograms dose developed antibodies measurable by ELISA. Six o...
متن کاملImmunogenicity and Safety of a 9-Valent HPV Vaccine.
OBJECTIVES Prophylactic vaccination of youngwomen aged 16 to 26 years with the 9-valent (6/11/16/18/31/33/45/52/58) human papillomavirus (HPV) virus-like particle (9vHPV) vaccine prevents infection and disease. We conducted a noninferiority immunogenicity study to bridge the findings in young women to girls and boys aged 9 to 15 years. METHODS Subjects (N = 3066) received a 3-dose regimen of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: East African Medical Journal
سال: 2009
ISSN: 0012-835X
DOI: 10.4314/eamj.v77i9.46690